Notably, none of the initial NSCLC tumors in these cases had known EGFR or ALK driver mutations, demonstrating that SCLC transformation can occur in contexts beyond those involving TKI therapies [32]. This evidence concerns the gene EGFR and small cell lung carcinoma.